Meeting
2017 ASCO Annual Meeting
A multicenter phase I trial of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814 in patients with solid tumors.
Authors
Mark van Bussel
The Netherlands Cancer Institute (NKI), Amsterdam, Netherlands
Mark van Bussel , Morten Mau-Soerensen , Lars Damstrup , Dorte Nielsen , Henk M.W. Verheul , Philippe Georges Aftimos , Maja J. De Jonge , Karin Berghoff , Jan H.M. Schellens
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT02316197
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2556)
DOI
10.1200/JCO.2017.35.15_suppl.2556
Abstract #
2556
Poster Bd #
48
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.
First Author: Dana Backlund Cardin
Poster
2016 ASCO Annual Meeting
First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.
First Author: Yong Sang Hong
Poster
2015 ASCO Annual Meeting
CTEP #8850: A phase I trial of riluzole and sorafenib in patients with advanced solid tumors.
First Author: Kristen Renee Spencer
Poster
2013 ASCO Annual Meeting
A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.
First Author: Joaquin Mateo